European Patent Office issues notice of allowance to Kuros' synthetic biomaterials

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today the allowance of European Patent Application 00910049 by the European Patent Office. This now allowed patent application is a key component of a broad portfolio of applications and patents designed to protect Kuros’ synthetic biomaterial (matrix) technologies and its product candidates which utilise this technology. This novel synthetic matrix platform is a key source of innovative products which will be important to Kuros’ future successful development

Kuros is developing a portfolio of biomaterial, and bioactive-biomaterial combination, products. The company’s product candidates are based on two different matrix technology platforms; synthetic or fibrin matrices. Kuros’ most advanced product candidate based on its synthetic technology is Kuros’ dural sealant product candidate (KUR-023) which is currently undergoing clinical evaluation in Europe. Kuros intends that this clinical study will enable CE marking in Europe.

Kuros’ most advanced products are based on a fibrin matrix and include KUR-111 and KUR-113 which have achieved positive results in Phase II trials for tibial plateau fractures and tibial shaft fractures respectively.

Mr. Didier Cowling, Chief Executive Officer at Kuros says: "Obtaining the notice of allowance for this European patent application further builds on Kuros’ proprietary position around its key synthetic matrix technology platform.  This platform is the basis of a number of Kuros’ novel product candidates and strengthening the IP position around these candidates adds significant value."

The now allowed claims cover broadly Kuros` proprietary method for forming biomaterials by nucleophilic addition mechanism starting from functionalized precursor components, such as functionalized PEGs. The claims cover the biomaterial (synthetic matrix), its method of production, kits for delivery and several uses. The allowance of the European application follows the grant of the US applications as patents no. US 7,744,912 and US 7,413,739 which were granted with similar broad claims, as well as the grant of the Canadian (CA 2,359,318), Mexican (MX 276585) and Australian (AU 773 914) applications.